Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER-2 Positive Breast Cancer × Doxorubicin × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 262 Triple Negative Breast Neoplasms 44 Breast Neoplasms, Male 17 Inflammatory Breast Neoplasms 14 Neoplasms 9 Neoplasm Metastasis 9 Cardiotoxicity 6 Sarcoma 4 Ovarian Neoplasms 4 Lymphoma, Non-Hodgkin 4 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Multiple Myeloma 3 Invasive Breast Cancer 3 Colorectal Neoplasms 3 Carcinoma, Ductal, Breast 3 Breast Diseases 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Pathologic Complete Response 2 Neutropenia 2 Myeloproliferative Disorders 2 Myelodysplastic-Myeloproliferative Diseases 2 Lung Neoplasms 2 Leukemia, Myelomonocytic, Chronic 2 Leukemia, Myeloid, Chronic-Phase 2 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2 Leukemia, Myeloid, Acute 2 Leukemia, Myeloid, Accelerated Phase 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Hodgkin Disease 2

Interventions

Trastuzumab 2 liposomal doxorubicin 1 eribulin 1 Metformin 1 Doxorubicin 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02488564 2025-02-03

met-HEReMYTA

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Completed

HER-2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡